Literature DB >> 11716037

Clonally related but phenotypically divergent human cancer cell lines derived from a single follicular thyroid cancer recurrence (TT2609).

A A Geldof1, J C van Mourik, M A Rooimans, F Arwert, M A Hermsen, I L Schadee-Eestermans, G A van Dongen, P van der Valk, P Lips, G J Teule.   

Abstract

Starting from different regional samples taken from a heterogeneous follicular thyroid cancer recurrence in a male patient, a series of cell cultures was initiated. Three stable cancer cell lines were successfully established (TT2609-A02, TT2609-B02, and TT2609-C02) and kept in continuous culture for more than 3 years. The lines are each characterized by a unique set of biological parameters such as morphology, ploidy state, cell proliferation rate, ultrastructure, thyroid marker expression, p53 expression, karyogram, agar clonogenic capacity and tumorigenicity as xenografts in nude mice. These characterization studies point to a marked heterogeneity at the level of the clinical tumor recurrence. Karyotype analysis of the cell lines showed a pattern of aberrations indicating that the lines are clonally related and that the A02 and C02 lines are subsequently derived from the more "original" tumor cell type B02 after a tetraploidization event. It is concluded that the obtained cell lines represent an in vitro/in vivo model for human follicular thyroid cancer. The availability of a series of cell lines for human follicular thyroid cancer, mimicking the biological heterogeneity observed in patient tumors, enables both detailed fundamental investigation of thyroid cancer cell biology and the experimental exploration of new treatment approaches.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11716037     DOI: 10.1089/105072501753210966

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  10 in total

1.  Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.

Authors:  Laura A Marlow; Stephen D Rohl; James L Miller; Jeffery A Knauf; James A Fagin; Mabel Ryder; Dragana Milosevic; Brian C Netzel; Stefan K Grebe; Honey V Reddi; Robert C Smallridge; John A Copland
Journal:  J Clin Endocrinol Metab       Date:  2018-09-01       Impact factor: 5.958

Review 2.  Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer.

Authors:  Tania Pilli; Kanteti V Prasad; Shankar Jayarama; Furio Pacini; Bellur S Prabhakar
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

3.  Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

Authors:  Rebecca E Schweppe; Joshua P Klopper; Christopher Korch; Umarani Pugazhenthi; Miriam Benezra; Jeffrey A Knauf; James A Fagin; Laura A Marlow; John A Copland; Robert C Smallridge; Bryan R Haugen
Journal:  J Clin Endocrinol Metab       Date:  2008-08-19       Impact factor: 5.958

4.  Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.

Authors:  Martina Broecker-Preuss; Stefan Müller; Martin Britten; Karl Worm; Kurt Werner Schmid; Klaus Mann; Dagmar Fuhrer
Journal:  BMC Cancer       Date:  2015-03-26       Impact factor: 4.430

5.  Induction of atypical cell death in thyroid carcinoma cells by the indirubin derivative 7-bromoindirubin-3'-oxime (7BIO).

Authors:  Martina Broecker-Preuss; Nina Becher-Boveleth; Susanne Gall; Katrin Rehmann; Susann Schenke; Klaus Mann
Journal:  Cancer Cell Int       Date:  2015-10-12       Impact factor: 5.722

6.  All-trans retinoic acid suppresses malignant characteristics of CD133-positive thyroid cancer stem cells and induces apoptosis.

Authors:  Dan Mei; Bin Lv; Bo Chen; Shan Xiao; Jie Jiang; Yan Xie; Ling Jiang
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

7.  Targeted Treatment Options of Recurrent Radioactive Iodine Refractory Hürthle Cell Cancer.

Authors:  Mehtap Derya Aydemirli; Willem Corver; Ruben Beuk; Paul Roepman; Nienke Solleveld-Westerink; Tom van Wezel; Ellen Kapiteijn; Hans Morreau
Journal:  Cancers (Basel)       Date:  2019-08-15       Impact factor: 6.639

8.  Characterization of human follicular thyroid cancer cell lines in preclinical mouse models.

Authors:  Ashley N Reeb; Andrea Ziegler; Reigh-Yi Lin
Journal:  Endocr Connect       Date:  2016-02-01       Impact factor: 3.335

9.  Survivin and XIAP - two potential biological targets in follicular thyroid carcinoma.

Authors:  Thomas A Werner; Levent Dizdar; Inga Nolten; Jasmin C Riemer; Sabrina Mersch; Sina C Schütte; Christiane Driemel; Pablo E Verde; Katharina Raba; Stefan A Topp; Matthias Schott; Wolfram T Knoefel; Andreas Krieg
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.996

10.  CXCR4/CXCR7/CXCL12-Axis in Follicular Thyroid Carcinoma.

Authors:  Thomas Artur Werner; Christina Maria Forster; Levent Dizdar; Pablo Emilio Verde; Katharina Raba; Matthias Schott; Wolfram Trudo Knoefel; Andreas Krieg
Journal:  J Cancer       Date:  2018-02-27       Impact factor: 4.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.